News Report · Nephrology

FDA Approves Sparsentan for Proteinuria Reduction: PDUFA June 2026 in FSGS Patients

June 08, 2026

FDA Approval Date

April 16, 2026

Recommended Dose

200 mg once daily

Clinical Perspective

The approval of sparsentan provides a new treatment option for patients with FSGS, addressing a critical need for effective therapies in this rare kidney condition.

Dr. Praveen Singh · Nephrology

Sparsentan (Filspari) reduced proteinuria by a statistically significant percentage in patients with focal segmental glomerulosclerosis (FSGS) versus standard care [1]. The FDA approved sparsentan for this indication on April 16, 2026, based on its efficacy demonstrated in clinical trials [2].

Clinical Context

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder characterized by scarring in the kidney's filtering units, leading to protein leakage into the urine. This condition can progress to kidney failure if left untreated, affecting both children and adults. Current treatment options primarily focus on managing symptoms and slowing disease progression, but many patients do not achieve adequate control of proteinuria with existing therapies. The approval of sparsentan represents a critical advancement in the treatment landscape for FSGS, providing a targeted approach to reduce proteinuria and potentially slow the decline in kidney function.

Key Findings

The clinical trial demonstrated that sparsentan reduced proteinuria by a statistically significant percentage compared to standard care [1].
The trial enrolled 300 patients aged eight years and older diagnosed with FSGS without nephrotic syndrome [2].
Event rates for proteinuria reduction were significantly higher in the sparsentan group compared to the control group [2].
The primary endpoint was the change in proteinuria levels from baseline [2].
Secondary analyses indicated improved kidney function metrics among those treated with sparsentan [2].
Sparsentan is administered at a dose of 200 mg once daily [2].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis reported with sparsentan — monitor throughout treatment and for at least 5 months after last dose [1].
Severe or fatal immune-mediated reactions occurred — withhold or permanently discontinue based on severity [1].
Infusion-related reactions reported — monitor during and after each infusion [1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception [1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for sparsentan (Filspari).

What This Means for Clinical Practice

Sparsentan is used in patients with FSGS who are eight years and older and do not have nephrotic syndrome. The significant reduction in proteinuria supports its use in managing this rare kidney condition. How this new treatment will be integrated into existing care protocols for FSGS remains to be established?

Study Design

The pivotal trial for sparsentan was a randomized, double-blind, placebo-controlled study involving 300 patients diagnosed with FSGS without nephrotic syndrome. The primary endpoint was the change in proteinuria levels from baseline, and the follow-up duration was 12 months. The study was funded by Travere Therapeutics, Inc., and key limitations included the lack of long-term safety data beyond the trial duration. Further research is needed to explore the long-term effects of sparsentan on kidney function and overall patient outcomes.

FAQ

What is sparsentan (Filspari) approved for?

Sparsentan is approved for the treatment of focal segmental glomerulosclerosis (FSGS) in patients aged eight years and older. The FDA granted this approval on April 16, 2026, based on clinical trial data showing significant proteinuria reduction compared to standard care.

How does sparsentan work?

Sparsentan is a dual endothelin and angiotensin II receptor antagonist. It targets pathways involved in kidney function and hypertension, differing from existing treatments that primarily focus on either endothelin or angiotensin pathways alone.

What is the recommended dose of sparsentan?

The recommended dose of sparsentan is 200 mg taken orally once daily. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for sparsentan (Filspari).

What are the most common side effects of sparsentan?

The most common side effects of sparsentan include peripheral edema, hypotension, hyperkalemia, dizziness, and anemia. The complete adverse event profile can be found in the prescribing information.

FDA Approves Sparsentan for Proteinuria Reduction: PDUFA June 2026 in FSGS Patients

FDA Approves Sparsentan for Proteinuria Reduction: PDUFA June 2026 in FSGS Patients

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly drug updates for Nephrology in your inbox.

Related Drug Updates

FDA Approves Finerenone for CKD: 18% Risk Reduction in FIDELIO-DKD Trial

Verified HCP Portal